C

CRISPR Therapeutics AG
D

CRSP

52.120
USD
0.46
(0.88%)
مغلق
حجم التداول
86,520
الربح لكل سهم
-5
العائد الربحي
-
P/E
-12
حجم السوق
4,501,275,210
أصول ذات صلة
A
ALLO
-0.00500
(-0.42%)
1.18500 USD
B
BEAM
0.060
(0.30%)
19.950 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
F
FATE
0.02000
(1.80%)
1.13000 USD
N
NTLA
-0.020
(-0.19%)
10.710 USD
S
SGMO
0.00200
(0.38%)
0.53200 USD
V
VCEL
0.130
(0.31%)
41.600 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: CRISPR Therapeutics AG

القطاع: Healthcare
الصناعة: Biotechnology
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.